AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21733988
Drug: Yoga program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yoga program (twice a week for 8 weeks)
Trial: 17089153
Drug: Carnitine supplementation
RxNorm normalized name: carnitine
DrugBank: Levocarnitine (DB00583)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carnitine supplementation (CS; n = 7, 4 g day(‐1))
Trial: 12215207
Drug: L-carnitine plus
RxNorm normalized name: L-Carnitine Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine plus zidovudine (AZT) and didanosine (DDI)
Trial: 12215207
Drug: zidovudine (AZT)
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: zidovudine (AZT) and didanosine (DDI) without L-carnitine
Trial: 1972375
Drug: Parenteral infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Parenteral infusion programs with varying carbohydrate and lipid content (up to 40% of total caloric content)
Trial: 1972375
Drug: Lipid solutions
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid solutions used as an energy source in early postoperative period
Trial: 31050952
Drug: PBM‐T alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PBM‐T alone (n = 17), low‐intensity laser (LIL) irradiation (wavelength 660 nm, continuous mode, spot energy 4 J, energy density 142 J/cm2, irradiation time 40 s per spot), once weekly for 4 weeks
Trial: 31050952
Drug: PBM‐T+PDT (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PBM‐T+PDT (n = 14), combination of PBM‐T and PDT with curcumin as photosensitizer, curcumin solution rinse for 5 min, blue light‐emitting diode irradiation for 5 min, LIL applied as in PBM‐T group
Trial: 20027357
Drug: Afala in
RxNorm normalized name: DIDECYLDIMONIUM CHLORIDE 2.5 mg in 0.001 L / BENZALKONIUM CHLORIDE 1 mg in 0.001 L TOPICAL GEL [Atala Bio Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afala in complex treatment
Trial: 15117299
Drug: Direct observation
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct observation of treatment by community health workers (CHWs)
Trial: 15117299
Drug: Direct observation
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct observation of treatment by family members
Trial: 8149522
Drug: Hirulog (direct
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hirulog (direct thrombin inhibitor)
Trial: 2970776
Drug: Intravenous tissue
RxNorm normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous tissue plasminogen activator (t‐PA) 150 mg over 8 hours
Trial: 2970776
Drug: Intravenous tissue
RxNorm normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous tissue plasminogen activator (t‐PA)
Trial: 21068351
Drug: High-cocoa flavanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-cocoa flavanol (HCF) group (494 mg cocoa flavanols/d)
Trial: 21068351
Drug: Low-cocoa flavanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-cocoa flavanol (LCF) group (23 mg cocoa flavanols/d)
Trial: 10873356
Drug: Augmentin 1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Augmentin 1.2 g (intravenous antibiotic prophylaxis)
Trial: 9093048
Drug: Tilt up
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tilt up guided treatment
Trial: 26321469
Drug: Combined Antioxidant
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined Antioxidant Therapy (CAT)
Trial: 10619581
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg ramipril daily for 6 weeks
Trial: 23764516
Drug: High-dose, high-repetition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose, high-repetition medical exercise therapy (MET)
Trial: 23764516
Drug: Low-dose, low-repetition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose, low-repetition exercise therapy (Control)
Trial: 19523680
Drug: Daily vaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily vaginal progesterone gel 90 mg
Trial: 17095018
Drug: Arundic acid
RxNorm normalized name: Arundic acid
DrugBank: Arundic acid (DB05343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arundic acid (AA) at 8 mg/kg/h
Trial: 7654156
Drug: Exposure‐based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure‐based treatment without formal cognitive restructuring
Trial: 2516883
Drug: Triamterene (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triamterene (100 mg orally)
Trial: 1105267
Drug: Clonidine at
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clonidine at a daily dose of 150 mug
Trial: 31003735
Drug: Once-daily prolonged-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily prolonged-release tacrolimus (PRT)
Trial: 26094993
Drug: Zonisamide 50
RxNorm normalized name: zonisamide 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zonisamide 50 mg/d
Trial: 26094993
Drug: Zonisamide 25
RxNorm normalized name: zonisamide 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zonisamide 25 mg/d
Trial: 21663812
Drug: Remifentanil 0.025
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 0.025 μg/kg/min (Group R25)
Trial: 21663812
Drug: Remifentanil 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 0.05 μg/kg/min (Group R50)
Trial: 21663812
Drug: Remifentanil 0.075
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 0.075 μg/kg/min (Group R75)
Trial: 7658999
Drug: Exercise-Propranolol test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise-Propranolol test (0.5 mg/kg weight)
Trial: 3098950
Drug: High calcium
RxNorm normalized name: Nutritional Supplement Oral Liquid [ENSURE HIGH CALCIUM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High calcium and phosphorus content parenteral nutrition (60-80 mg Ca and 46.5-62 mg P/dl)
Trial: 3098950
Drug: Low calcium
RxNorm normalized name: Dianeal Low Calcium 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low calcium and phosphorus content parenteral nutrition (20 mg Ca and 15.5 mg P/dl)
Trial: 27745535
Drug: Usual outpatient
RxNorm normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual outpatient mental health treatment
Trial: 25901477
Drug: Opioid +
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid + pain (intravenous fentanyl 1 μg/kg and cold-pressor pain)
Trial: 25901477
Drug: Opioid only
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid only (intravenous fentanyl 1 μg/kg)
Trial: 26346805
Drug: Initial Conservative
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial Conservative Treatment
Trial: 2045530
Drug: Captopril (0.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (0.7 mg/kg for young, 1.2 mg/kg for elderly)
Trial: 6861601
Drug: Phenobarbital 5
RxNorm normalized name: phenobarbital 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenobarbital 5 mg/kg/day for 5 to 12 months
Trial: 29768147
Drug: Budesonide-formoterol used
RxNorm normalized name: budesonide / formoterol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide-formoterol used as needed (200 μg of budesonide and 6 μg of formoterol)
Trial: 29768147
Drug: Budesonide maintenance
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide maintenance therapy (200 μg of budesonide plus terbutaline 0.5 mg used as needed)
Trial: 29768147
Drug: Budesonide maintenance
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide maintenance therapy
Trial: 27001560
Drug: Control (routine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (routine treatment and care)
Trial: 23157902
Drug: Clopidogrel combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel combined with warfarin (group B)
Trial: 17106432
Drug: Gabapentin 1800
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin 1800 mg daily
Trial: 23997137
Drug: Intermittent pneumatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent pneumatic compression (IPC) of the foot for at least six hours daily under a plaster cast for two weeks
Trial: 8878342
Drug: Citalopram (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (20 mg, acute dose)
Trial: 8878342
Drug: Citalopram (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (20 mg/day for 14 days, chronic dose)
Trial: 27741345
Drug: Efinaconazole topical
RxNorm normalized name: efinaconazole topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efinaconazole topical solution (10%)
Trial: 24038028
Drug: Higher doses
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher doses of corticosteroid
Trial: 20028946
Drug: Insulin and
RxNorm normalized name: Isophane insulin and porcine regular insulin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin and glucose infusion (euglycemic-hyperinsulinemic clamp)
Trial: 20028946
Drug: Insulin and
RxNorm normalized name: Isophane insulin and porcine regular insulin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin and glucose infusion plus Intralipid and heparin infusion
Trial: 17010005
Drug: Naftopidil monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naftopidil monotherapy (25-75 mg/day)
Trial: 17010005
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (25-75 mg/day of naftopidil and 10-20 mg/day of propiverine hydrochloride or 2-6 mg/day of oxybutynin hydrochloride)
Trial: 12705171
Drug: 0.05% azelastine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% azelastine eye drops, twice daily
Trial: 10632236
Drug: Sertraline (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (up to 200 mg/d)
Trial: 10632236
Drug: Desipramine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desipramine (up to 300 mg/d)
Trial: 11788107
Drug: 20-40 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20-40 mg/day lovastatin
Trial: 1330434
Drug: 1 mg/day
RxNorm normalized name: Lyllana 0.1 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/day (minidose) warfarin
Trial: 1330434
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 20-40 mg/day lovastatin and 1 mg/day warfarin
Trial: 1330434
Drug: Warfarin placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin placebo
Trial: 1330434
Drug: Low-dose (81
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose (81 mg/day) aspirin
Trial: 19243753
Drug: Combination hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combination hormone therapy (HT), 5 microg ethinyl E(2) and 1 mg norethindrone acetate for 4 weeks
Trial: 15819765
Drug: Diamorphine 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diamorphine 0.25 mg (D)
Trial: 15819765
Drug: Fentanyl 15
RxNorm normalized name: fentaNYL 150 mcg/30 mL-D5% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 15 microg plus diamorphine 0.25 mg (FD)
Trial: 11899505
Drug: Albumin infusion
RxNorm normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albumin infusion with large-volume paracentesis
Trial: 11899505
Drug: Albumin infusion
RxNorm normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albumin infusion in selected patients
Trial: 11899505
Drug: Albumin infusion
RxNorm normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albumin infusion with vasopressin analogue
Trial: 10980827
Drug: Secondary preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secondary preventive therapies (statin drugs and aspirin)
Trial: 7669490
Drug: R 56865
RxNorm normalized name: R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R 56865 (20 mg)
Trial: 7669490
Drug: R 56865
RxNorm normalized name: R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R 56865 (30 mg)
Trial: 7669490
Drug: R 56865
RxNorm normalized name: R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R 56865 (40 mg)
Trial: 2288834
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of eltoprazine (8 mg)
Trial: 2288834
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of eltoprazine (3 mg)
Trial: 2288834
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of eltoprazine (8 mg)
Trial: 7026073
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus mastectomy (surgery)
Trial: 7026073
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment groups (chemotherapy plus mastectomy and chemotherapy plus radiotherapy)
Trial: 7026073
Drug: Surgical group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical group (chemotherapy plus mastectomy)
Trial: 21078950
Drug: PNU-100480 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PNU-100480 at 600 mg twice daily for 28 days
Trial: 21078950
Drug: Linezolid at
RxNorm normalized name: Linezolid
DrugBank: Linezolid (DB00601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Linezolid at 300 mg daily for 4 days
Trial: 21382958
Drug: Polarity Therapy
RxNorm normalized name: Adlarity
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Polarity Therapy (PT)
Trial: 12014063
Drug: Fexofenadine 180
RxNorm normalized name: fexofenadine 180 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fexofenadine 180 mg OD for 3 weeks followed by randomization to fexofenadine or placebo for another 3 weeks
Trial: 10221688
Drug: Trimegestone (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimegestone (various doses) with micronized oestradiol (2 mg/day)
Trial: 16903597
Drug: Scraping therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scraping therapy and warming acupuncture-moxibustion
Trial: 6315050
Drug: Wholemeal bread
RxNorm normalized name: Wholemeal bread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wholemeal bread (phytate 2.2 mmol, non-starch polysaccharide 18.7 g)
Trial: 6315050
Drug: Brown bread
RxNorm normalized name: Brown bread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brown bread (phytate 2.1 mmol, non-starch polysaccharide 10.9 g)
Trial: 6315050
Drug: White bread
RxNorm normalized name: White bread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White bread (phytate 2.3 mmol, non-starch polysaccharide 3.3 g)
Trial: 29428473
Drug: Blood loss
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood loss ≥500 mL
Trial: 26374448
Drug: Leptin antagonist
RxNorm normalized name: leptin
DrugBank: Leptin (DB05098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leptin antagonist (in vitro experiments)
Trial: 19180337
Drug: Oscillating positive
RxNorm normalized name: AerobiKA Oscillating Positive Expiratory Pressure Device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oscillating positive expiratory pressure maneuvers followed by forced expiratory technique sequences with inhaled hypertonic saline (3%, 4% or 5%) in asthma patients (A/I)
Trial: 19180337
Drug: Oscillating positive
RxNorm normalized name: AerobiKA Oscillating Positive Expiratory Pressure Device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oscillating positive expiratory pressure maneuvers followed by forced expiratory technique sequences with inhaled hypertonic saline (3%, 4% or 5%) in COPD patients (C/I)
Trial: 12462513
Drug: Nonpharmacological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonpharmacological treatment (vagal tone increase)
Trial: 12462513
Drug: Nonpharmacological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonpharmacological treatment (little change in vagal tone)
Trial: 10690132
Drug: Omitting ACE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omitting ACE inhibitor medication before surgery
Trial: 10690132
Drug: Continuing ACE
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuing ACE inhibitor medication before surgery
Trial: 1984377
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg epidural morphine with 3 mL of normal saline (group 1)
Trial: 1984377
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg epidural morphine with 1 mg butorphanol and 2 mL of normal saline (group 2)
Trial: 1984377
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg epidural morphine with 3 mg butorphanol (group 3)
Trial: 25087057
Drug: Droperidol (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol (75 mcg/kg) administered after cardiopulmonary bypass
Trial: 23474908
Drug: Ticagrelor with
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor with low-dose acetylsalicylic acid (ASA) (≤150 mg)
Trial: 23474908
Drug: Clopidogrel with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel with low-dose acetylsalicylic acid (ASA) (≤150 mg)
Trial: 21704242
Drug: Etamicastat 100
RxNorm normalized name: Etamicastat
DrugBank: Etamicastat (DB15288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etamicastat 100 mg single dose
Trial: 21704242
Drug: Etamicastat 100
RxNorm normalized name: Etamicastat
DrugBank: Etamicastat (DB15288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etamicastat 100 mg/day for 7 days
Trial: 21704242
Drug: Etamicastat single
RxNorm normalized name: Etamicastat
DrugBank: Etamicastat (DB15288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etamicastat single dose
Trial: 19428083
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 600 mg/d orally for 3 months
Trial: 12426514
Drug: Rifampin 600
RxNorm normalized name: rifampin 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin 600 mg orally once daily for 5 days (phase 2)
Trial: 23904065
Drug: Intravenous hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous hydrocortisone (11 infants)
Trial: 23276234
Drug: Individual Placement
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual Placement and Support + treatment as usual
Trial: 20189226
Drug: Doxazosin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin (2 mg daily at night) along with diclofenac sodium 50 mg
Trial: 16146478
Drug: Intra-articular injection
RxNorm normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection of bupivacaine (20 ml of 2.5 mg/ml) 30 min before skin incision
Trial: 16146478
Drug: Post-operative administration
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-operative administration of bupivacaine (20 ml of 2.5 mg/ml) after skin closure
Trial: 12182256
Drug: Clindamycin phosphate
RxNorm normalized name: Clindamycin Phosphate
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clindamycin phosphate 1%/benzoyl peroxide 5% gel formulation
Trial: 12182256
Drug: Clindamycin 1%
RxNorm normalized name: BENZOYL PRX 5%/CLINDAMYCIN 1% GEL KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin 1% gel (monotherapy)
Trial: 10202871
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of clomiphene citrate on days 1-5 and placebo on days 5-9
Trial: 8539022
Drug: Dapiprazole 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapiprazole 0.5% ophthalmic solution
Trial: 2222553
Drug: Placebo formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo formulations (i.v. solution; p.o. solution; p.o. solid forms)
Trial: 2222553
Drug: H1-antagonist positive
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: H1-antagonist positive control
Trial: 12972527
Drug: Health-related quality
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Health-related quality of life (HRQOL) evaluation in treatment arms